DataMeds AI, Inc. — Form 8-K
Filed November 17, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 76/100
What the filing says
DataMeds AI, Inc. established an At-The-Market (ATM) offering agreement dated November 16, 2026, with Dawson James Securities, Inc. to sell up to $7,045,403 of common stock pursuant to Form S-3 registration (No. 333-295078). The prospectus supplement was filed November 17, 2026. This is counsel's opinion letter confirming the shares are duly authorized and validly issuable under Delaware law.
Why this rating
ATM offering of $7.0M is 26% of company's $27.1M market cap—material dilution risk. Meaningfully significant for near-term capital structure, though outcome depends on actual sales pace and use of proceeds not disclosed here.
Price action (we called it neutral)
before filing · preread $0.61 ▼ 7.17% | at our read · unknown $0.66 | +10 min · unknown $0.65 ▼ 1.25% | +30 min · unknown $0.69 ▲ 4.30% | +1 hr · unknown $0.69 ▲ 3.82% | +4 hrs · unknown $0.73 ▲ 10.26% |
The stock had already moved +7.72% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.